[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"congestive-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:congestive-heart-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,47,71,102,125,154,185,207,241,260,288,311,332,362,392,417,443,472,492,517],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100600379","boston-medical-center-ultrasound-decongestion-study-in-heart-failure-100600379",false,"NCT07096726","Boston Medical Center Ultrasound Decongestion Study in Heart Failure","Boston Medical Center Ultrasound Decongestion Study","BUDS-HF","Inclusion Criteria:\n\n* Patient with a primary diagnosis of acute on chronic decompensated heart failure who is admitted to inpatient or presents to the outpatient Boston Medical Center (BMC) Heart Failure Infusion clinic for decongestion treatment.\n* Willing and able to receive short abdominal and thoracic ultrasounds throughout hospitalization\n* Patients with right and\u002For left ventricular failure\n\nExclusion Criteria:\n\n* Hemodynamic instability defined as systolic blood pressure \\\u003C85 mmHg or mean arterial pressure \\\u003C60 mm Hg for greater than 24 hours duration\n* Abdominal surgery in the past 1 month\n* Significant acute or chronic liver disease\n* End stage renal disease on dialysis\n* Advanced chronic kidney disease (CKD) \\[Stage V CKD with glomerular filtration rate (GFR) \\\u003C15\\] to exclude renal vein doppler ultrasound\n* Severe acute kidney injury (AKI) or requiring renal replacement therapy\n* Known abdominal thrombus in the inferior vena cava (IVC) or portal vein\n* Acute myocarditis\n* Acute valvular disease\n* Acute type 1 myocardial infarction\n* Medical condition precluding abdominal ultrasound due to significant discomfort or pain\n* Adults not able to provide consent (a simple teach back method of key aspects discussed in consent form will be utilized to verify if patient is able to adequately provide informed consent)","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to analyze the utility of a novel five-point ultrasound as a predictor of volume overload in diverse patients who are admitted with volume overload\u002Fcongestive heart failure (CHF) exacerbation at Boston Medical Center (BMC), the largest safety-net hospital in New England. Current standard of care (SOC) involves the utilization of laboratory markers and physical exam, which is often inconsistent and equivocal. The investigators will assess will assess if ultrasound-assisted diuresis reduces recurrent episodes of volume overload\u002Fdecompensated heart failure.",[27,28],"Congestive Heart Failure","Volume Overload",[30,31,32,33],"Venous Excess Ultrasound (VExUS)","Ultrasound-assisted diuresis","Heart Failure with Preserved Ejection Fraction (HFpEF)","Heart Failure with Reduced Ejection Fraction (HFrEF)","NOT_YET_RECRUITING","2026-06-29",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":21},"2026-09",{"date":42,"type":21},"2027-12",{"name":44,"class":45},"Boston Medical Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100620378","palliative-care-for-people-with-hf-100620378","NCT07356843","Palliative Care for People With HF","Implementing Community Palliative Care for People With Heart Failure","Inclusion Criteria:\n\n* Outpatient clinician or staff member (e.g. physician, physician assistant, nurse practitioner, registered nurse, social worker, psychologist, medical assistant) or healthcare leadership personnel (e.g. Chief Nursing Officer, Clinic Medical Director etc.)\n* at least 6 months of experience caring for patients with HF\n* 18 years or older\n\nExclusion Criteria:\n\n\\-",{"count":5,"type":21},"OBSERVATIONAL","Imagine having heart failure, a condition where the heart struggles to pump blood, making daily life hard. People with heart failure often don't feel well and end up going to the hospital a lot. Many of these people could feel better with extra help, but there aren't many programs that offer support beyond usual heart failure treatments. That's where the ADAPT program comes in, which stands for \"Advancing Symptom Alleviation with Palliative Treatment.\" In this program, nurses and social workers call people weekly, helping them manage their toughest symptoms, offering tools to cope with heart failure, and keeping the patients' current doctors involved. We tested this program in a research study with heart failure patients and found that it improved their quality of life and lowered depression, anxiety, and heart failure symptoms. The question now is if the ADAPT program will work in the community, outside of a research setting, so that more people could benefit from it. Specifically, can the ADAPT program work well in new places? Will patients and their families find it helpful? Most importantly, can it help improve the lives of people with heart failure in these new settings? To answer these questions, the study team will work with healthcare providers to 1) ask how to adjust the ADAPT program to work well in various settings (e.g. primary care, heart failure clinic) and 2) use this information to create simple materials and trainings to help them easily provide ADAPT. This will prepare for the next phase of this project to test out the new ADAPT program.",[27,58,59,60],"Congestive Heart Failure(CHF)","Congestive Heart Failure (CHF)","Congestive Heart Failure Chronic","RECRUITING","2026-06-15",{"date":64,"type":38},"2026-06-16",{"date":66,"type":38},"2025-10-29",{"date":68,"type":21},"2028-09",{"name":70,"class":45},"Indiana University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":4},"100640782","a-clinical-study-used-to-estimate-central-venous-pressure-non-invasively-using-occlusion-pressure-100640782","NCT07583680","A Clinical Study Used to Estimate Central Venous Pressure Non-invasively Using Occlusion Pressure","Non-Invasive Central Venous Pressure Estimation Using Occlusion Pressure: A Novel Approach for Accurate Hemodynamic Monitoring","CV-PRO","Inclusion Criteria:\n\n* Admitted to PICU or PCICU\n* Provided written informed consent\n* Continuous Central venous pressure monitoring transduced from a standard central venous catheter (not PICC line)\n\nExclusion Criteria:\n\n* Glenn and Fontan Patients\n* Heterotaxy Syndrome Patients\n* Inability to consent by guardian\u002Fcaretaker","17 Years",{"count":81,"type":21},30,"The purpose of this study is to collect different measurements using a method called peripheral venous pressure (PVP). PVP checks the pressure in the veins in the arms or legs. It can give doctors a good idea of how well the heart is working, similar to another method called central venous pressure (CVP), which doctors use in hospitals. In this study, the research team will measure PVP in people aged 0-17. The researcher hopes that this data will help doctors understand how PVP measurements relate to health outcomes, which could lead to better ways to diagnose and treat patients in the future.\n\nThe peripheral venous pressure (PVP) device will be used to non-invasively measure the pressure required to stop blood flow in the forearm, which will indirectly measure the PVP in the forearm. This device is composed of a pressure sensor and a Doppler flow detector that will be connected to a research laptop for data collection. This device will be placed on the forearm.\n\nIf you agree to be in this study, the study team will monitor the venous flow rate (the amount of blood moving through the veins over a certain period of time) using a Doppler Flow Detector while applying pressure to the vein with a pressure sensor. This will take place on the forearm.\n\nThe internal jugular vein will be identified and recorded using ultrasound imaging and Doppler sensor.\n\nThe forearm vein will be identified and marked using ultrasound imaging. Pressure will be applied for 15 seconds, and then stopped and repeated 4 times, making five sets of measurements.\n\nThe procedure may be repeated in 2-3 additional sessions during the hospital stay, if necessary.\n\nYour participation in this study will last approximately 30 minutes.\n\nThis procedure is for research only and will not affect your regular care. This will occur during your child's stay in the PCICU\u002FPICU. No additional study visits will be required.\n\nThe following procedures are being performed for research purposes only:\n\nCopying information such as your medical history from your medical record; Obtaining non-invasive peripheral venous pressure measurements.",[84,27],"Pediatric Congestive Heart Failure",[86,87,88,89,84,27,90,91,92,93],"CHF","Pediatric CHF","Congenital Heart Disease","Pediatric Congenital Heart Disease","Heart Failure","CVP","Central Venous Pressure","CVP Monitor","2026-05-06",{"date":96,"type":38},"2026-05-13",{"date":98,"type":21},"2026-07",{"date":42,"type":21},{"name":101,"class":45},"Le Bonheur Children's Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":46},"100623700","peripheral-venous-pressure-pvp-trial-100623700","NCT07400042","Peripheral Venous Pressure (PVP) Trial","Reducing the Length of Stay and Incidence of Rehospitalization in Heart Failure Patients by Measuring Peripheral Venous Pressure; a Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients with minimum 3-month history of Congestive Heart Failure admitted to Aurora St. Luke's Medical Center with acute decompensation\n* English speaking only\n\nExclusion Criteria:\n\n* Patients who do not already have a peripheral IV line inserted\n* Patients whose IV line cannot be transduced\n* Patients with current or past vein thrombosis in the arm used to measure the pressure or with history of recurrent (\\>1) pulmonary embolism\n* Patients with active thrombophlebitis in the arm\n* Patients who have experienced a major cardiovascular event (myocardial infarction, stroke, etc.) ≤2 months prior to the admission date\n* Patients who have received an implanted cardiac resynchronization device (pacemaker or ICD) ≤3 months prior to admission date\n* Patients enrolled in other cardiovascular research studies.\n* Patients with a clinical condition that the investigator believes may not allow the patient to complete the study, at the discretion of the investigator. Examples of conditions that may apply include severe stenotic valvular disease, isolated right ventricle failure, precapillary pulmonary hypertension, hypertrophic obstructive cardiomyopathy, implanted left ventricular assist device, history of heart transplantation, clinical diagnosis of cardiogenic shock, any left-to-right shunt\n* Patients with congenital heart disease or mechanical right heart valve(s)\n* Planned heart surgery and\u002For coronary intervention during hospitalization\n* Patients expected to receive heart transplant within 6 months of admission\n* IV cannula smaller than 22G\n* Patients who are pregnant and\u002For lactating\n* Patients who are unable to provide informed consent\n* Patients who are intubated",{"count":110,"type":21},600,[24],"The purpose of the study is to determine if there is a reduction in the length of stay and rates of rehospitalization for patients diagnosed with congestive heart failure when physicians are provided daily measurements of peripheral venous pressure versus no daily measurements of peripheral venous pressure.",[27],[115],"peripheral venous pressure","2026-04-23",{"date":118,"type":38},"2026-04-24",{"date":120,"type":21},"2026-06",{"date":122,"type":21},"2031-08",{"name":124,"class":45},"Wake Forest University Health Sciences",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100460483","phase-4-optimized-treatment-of-pulmonary-edema-or-congestion-100460483","NCT05276219","Optimized Treatment of Pulmonary Edema or Congestion","Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial","Decongest","Inclusion criteria\n\n1. Age ≥ 18 years\n2. Acute (within minutes to days) onset or worsening of subjective dyspnea\\*\n3. Systolic blood pressure ≥100 mmHg\n4. Oxygen saturation \\\u003C94% or need of oxygen\n5. Signs or suspicion of congestion (peripheral edema, rales, and\u002For clinical suspicion of congestion) \\*\n\n   * by the best assessment from a medical doctor. Inclusion must not wait on x-ray or other measures: patients suspected of pulmonary congestion should be included immediately.\n\nExclusion criteria\n\n1. More than 40 mg IV furosemide within the last three hours before randomization including prehospital treatment.\n2. More than 3 hours from hospital-admission to randomization\n3. Ongoing ventricular taky- or brady-arrythmias or supraventricular arrhythmias with HR \\> 180 or \\\u003C 40 bpm.\n4. Suspected severe infection or sepsis.\n\nExclusion criteria are purposely liberal, so patients can be included in accordance with everyday clinical practice. However, a safety criterion will be implemented:\n\nIf blood pressure drops below 90 mmHg in 2 measurements with 5 minutes apart and\u002For if urine production is below 50 ml after 1 hour, the intervention will be stopped, and patients can receive furosemide and nitrates freely.\n\nWe purposely chose not to exclude patients with aortic stenosis, since observational studies did not find excess risk of given nitrates to patients with pulmonary edema and aortic stenosis",{"count":134,"type":21},1104,[136],"PHASE4","Background:\n\nIntravenous (IV) loop-diuretics have been a key component in treating pulmonary edema since the nineteen sixties and has a Class 1 recommendation in the 2021 European Society of Cardiology guidelines for heart failure. Conversely, vasodilation was downgraded in the treatment of acute heart failure due to a lack of trials that compare vasodilation with loop-diuretics in a hyperacute clinical setting. This clinical equipoise will be tested in a trial including patients with pulmonary congestion immediately at hospital admission.\n\nPrimary objective:\n\nTo determine the superior strategy of loop-diuretics (furosemide), vasodilation (nitrates) or the combination during emergency treatment.\n\nDesign: Investigator-initiated, randomized, double-blinded, placebo-controlled trial with 1:1:1 allocation.\n\nIntervention:\n\nIntervention-phase will last 6 hours from study-inclusion, and patients will be allocated to one of three groups:\n\n* Boluses of 40 mg IV furosemide + nitrate-placebo as soon as possible and repeated up to 10 times.\n* Boluses of 3 mg IV isosorbide dinitrate + furosemide-placebo as soon as possible.\n* Boluses of both 3 mg IV isosorbide dinitrate + of 40 mg as soon as possible.",[139,27,140],"Pulmonary Edema","Acute Heart Failure",[142,143],"acute heart failure","Pulmonary edema","2026-04-17",{"date":146,"type":38},"2026-04-22",{"date":148,"type":38},"2023-09-14",{"date":150,"type":21},"2027-05-31",{"name":152,"class":45},"Rigshospitalet, Denmark",4,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":161,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":171,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100630068","routine-versus-provisional-distal-perfusion-catheter-placement-in-patients-undergoing-mechanical-circulatory-support-100630068","NCT07482865","Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support","PERFUSE-MCS","Inclusion Criteria:\n\n* Patients aged 19 years old\n* Cardiogenic shock requiring mechanical circulatory support through femoral artery approach\n* Subject who can verbally confirm understandings of risks and benefits of receiving distal perfusion catheter insertion and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n* Under the critically-ill clinical circumstance (unclear consciousness of patient), legally authorized representative can provide written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Apparent symptoms and sign of acute limb ischemia immediately after mechanical circulatory support insertion\n* Significant coagulopathy precluding invasive procedure due to high risk of bleeding\n* Pregnant women, women with potential childbearing, or lactating women\n* Irreversible limb ischemia requiring interventional procedures or surgery at the time of MCS insertion\n* Previous history if femoral-femoral bypass grafting or femoral-popliteal bypass grafting\n* Previous history of limb amputation\n* Unwilling or unable to obtain informed consent from the participant or legally authorized representative","19 Years",{"count":163,"type":21},500,[24],"A prospective, multi-center, open label, randomized controlled, superiority trial to compare clinical outcomes between routine distal perfusion catheter (DPC) insertion versus provisional distal perfusion catheter (DPC) insertion in the occurrence of sign or symptom of acute limb ischemia in patients undergoing mechanical circulatory support (MCS) through femoral artery approach.",[167,168,27,169,170],"Cardiogenic Shock","Acute Myocardial Infarction of Inferior Wall","Myocarditis","Acute Limb Ischemia",[167,172,173,27,174],"Distal perfusion catherter","Acute Myocardial Infarction","Limb ischemia","2026-03-18",{"date":177,"type":38},"2026-03-20",{"date":179,"type":21},"2026-05-01",{"date":181,"type":21},"2030-10-31",{"name":183,"class":45},"Samsung Medical Center",6,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100478277","trpc6-characterization-to-predict-and-prevent-chemotherapy-related-cardiomyopathy-and-heart-failure-with-breast-cancer-100478277","NCT05507879","TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer","Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study)","Inclusion Criteria:\n\n* 18 years of age or older\n* Any breast cancer patient initiating doxorubicin\u002Fother anthracycline and patients receiving trastuzumab without doxorubicin\u002Fanthracycline in the neoadjuvant\u002Fadjuvant setting\n* An understanding of the protocol and its requirements, risks, and discomforts\n* The ability and willingness to sign an informed consent\n* Diagnosed with therapy related cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment OR completed chemotherapy with no cardiotoxicity at least two years post treatment OR patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include doxorubicin chemotherapy, or trastuzumab.\n* Healthy, non-pregnant, adult subjects who weigh at least 110 pounds\n\nExclusion Criteria:\n\n* Inability on the part of the patient to understand the informed consent or be compliant with the protocol\n* Anemia with hemoglobin less than 8\n* Patients not willing to undergo a blood draw\n* Patients with stage IV or distant metastatic breast cancer",{"count":20,"type":21},"This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer. Cardiac toxicity, changes in heart function is a well-recognized complication of certain cancer related therapies. Understanding these changes may allow early intervention against therapy-related cardiac toxicity and also identify novel therapeutic targets to protect patient long-term cardiac health. Studying samples of blood from patients with breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA), identify biomarkers related to cardiac toxicity, and prevent the development of therapy-induced cardiac toxicity in patients receiving chemotherapy.",[195,196,27],"Breast Carcinoma","Cardiomyopathy","2026-02-06",{"date":199,"type":38},"2026-02-10",{"date":201,"type":38},"2022-09-26",{"date":203,"type":21},"2027-09-01",{"name":205,"class":45},"Mayo Clinic",2,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":206},"100544852","pharmacy-led-transitions-of-care-intervention-to-improve-medication-adherence-100544852","NCT06374277","Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence","Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations","MedAAAction","Inclusion Criteria:\n\n* Medicaid or uninsured inpatients\n* 21 years or older\n* ≥2 of the complex chronic conditions during index admission or prescribed\u002Fusing ≥2 chronic medications for these conditions\n* Patients receiving chronic disease medications from the hospital pharmacy.\n* Patients will be eligible if they have multiple complex chronic conditions including diabetes, hypertension, high cholesterol, coronary artery disease, congestive heart failure, chronic lung disease, chronic kidney disease, arrhythmia, stroke, psychiatric disorders including depression and anxiety, or who are prescribed or using anticoagulants.\n\nExclusion Criteria:\n\n* Medicare and Medicaid dual eligible patients.\n* If the primary reason for the index admission is related to cancer, pregnancy, or a surgical procedure for an acute problem\n* If patients have diagnoses of active psychosis, substance abuse, or suicidal ideation during the index admission.\n* If the planned discharge location is not home.\n* If patients are part of an existing pharmacy discharge program.",{"count":216,"type":21},388,[24],"Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians\u002Fhealth coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.",[220,221,222,223,27,224,225,226,227,228,229,230,231],"Diabetes","Hypertension","High Cholesterol\u002FHyperlipidemia","Coronary Artery Disease","Chronic Lung Disease","Chronic Kidney Diseases","Arrythmia","Stroke","Depression","Anxiety","Pulmonary Embolism","Heart Attack","2026-01-27",{"date":234,"type":38},"2026-01-29",{"date":236,"type":38},"2024-04-06",{"date":238,"type":21},"2028-01-31",{"name":240,"class":45},"University of Tennessee",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":206},"100404837","stress-and-congestive-heart-failure-100404837","NCT04551560","Stress and Congestive Heart Failure","Inclusion Criteria:\n\n-Heart failure patients over 18 who have or will be receiving a Cardiomems implanted PAP monitor.\n\nExclusion Criteria:\n\n* Patients who are unable to perform EMA or laboratory assessments due to cognitive, visual, language, or other disabilities will be excluded.\n* Patients with Class IV heart failure will also be excluded, as they are already maximally decompensated, and a ceiling\u002Ffloor effect would preclude effects of stress.\n* Patients with conditions other than heart failure that affect PA pressures (e.g. dialysis).\n* Patients with physical conditions that interfere with study participation.\n* Patients non-compliant with their PAP monitoring.\n* Patients with chronic opioid use will be excluded.",{"count":248,"type":21},112,[24],"The purpose of this study is to investigate whether acute stress can precipitate congestive heart failure (CHF) exacerbation in patients with CHF.",[27],"2026-01-26",{"date":232,"type":38},{"date":255,"type":38},"2020-12-02",{"date":257,"type":21},"2026-04-30",{"name":259,"class":45},"Yale University",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":277,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":46},"100593973","a-prospective-evaluation-of-clinical-outcomes-in-acute-ischemic-stroke-after-endovascular-treatment-wdoppler-100593973","NCT07013396","A Prospective Evaluation of Clinical Outcomes in Acute Ischemic Stroke After Endovascular Treatment w\u002FDoppler","A Prospective Evaluation of Clinical Outcomes in Acute Ischemic Stroke After Endovascular Treatment Using Transcranial","Inclusion Criteria:\n\n* Anterior circulation stroke including ACA, MCA or ICA stroke that underwent EVT including tandem occlusions.\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Difficulty in detecting the acoustic window by TCD\n* Pregnancy\n* Incarcerated patients",{"count":268,"type":21},100,[24],"Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \\[1\\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.",[272,273,274,223,275,27,220,276],"Anterior Cerebral Artery Syndrome","Anterior Cerebral Artery Stroke","Acute Ischemic Stroke","Cardioembolic Stroke","Vasogenic Cerebral Edema",[278,279],"systolic blood pressure","Transcranial Doppler","2025-11-21",{"date":282,"type":38},"2025-11-25",{"date":284,"type":21},"2027-02",{"date":284,"type":21},{"name":287,"class":45},"Virginia Commonwealth University",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":294,"sex":17,"minAge":295,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":46},"100520015","care-transitions-app-for-patients-with-multiple-chronic-conditions-100520015","NCT06051058","Care Transitions App for Patients With Multiple Chronic Conditions","Inclusion Criteria:\n\n* Adult patients (55+) with a Brigham PCP or appointment in one of the 15 locations discharging from a BWH general medicine unit\n* Discharging to home, home health care service or assisted living\n* Fluent in spoken English in patient or healthcare proxy\n* Patients with at least one of the conditions listed below + one additional chronic condition on the problem list.\n* Patient with heart failure on the problem list\n* Patient with type 2 diabetes on the problem list\n* Patient with chronic kidney disease on the problem list\n\nExclusion Criteria:\n\n* Adult patients (55+) with Westwood, Pembroke, or Transition Clinic PCP admitted to ICU, OBGYN, Surgical, Cardiology, Oncology, Orthopedics, or other Specialty Unit\n* Pregnant\n* Prisoner, institutionalized individual or in police custody\n* Discharge planned within 3 hours of screening\n* Patient too ill to participate or with active psychosis\u002Fserious mental illness, delirium, or severe dementia\n* Not fluent in spoken English in patient and health proxy\n* Unlikely to be discharged to home\n* Lacks a device capable of accessing the app\n* Lack of a working telephone for 30-day follow-up",true,"55 Years",{"count":297,"type":21},798,[24],"The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.",[90,27,220,301,225],"Diabetes Mellitus","2025-11-12",{"date":304,"type":38},"2025-11-13",{"date":306,"type":38},"2024-10-08",{"date":308,"type":21},"2026-12",{"name":310,"class":45},"Brigham and Women's Hospital",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":294,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":46},"100114995","circulating-markers-for-ischemic-heart-disease-100114995","NCT00762333","Circulating Markers for Ischemic Heart Disease","Inclusion Criteria:\n\n* men and women, 18 years of age and over with acute myocardial infarction (determined by positive cardiac markers -CKMB\u002F troponin) with or without heart failure (dyspnea, rales, edema, elevated jugular venous pressure, ascites).\n* Heart failure can be diagnosed using imaging evidence such as dilated heart, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures\n* A control group of male subjects age 60 and older without history of MI or heart disease\n\nExclusion Criteria:\n\n* Subjects unable to give consent\n* Subjects who have undergone cardiac or non-cardiac surgery in the 3 months prior to enrollment",{"count":318,"type":21},550,"The purpose of this research is to determine if two proteins in the blood are increased during acute myocardial infarction and whether their levels are higher in those who develop heart failure than those who do not. These two proteins are produced and potentially released when the heart muscle is damaged. They may then be released into the blood and be detected by standard method in the research laboratory. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or myocardial infarction.",[321,322,27],"Myocardial Infarction","Ischemia","2025-08-10",{"date":325,"type":38},"2025-08-12",{"date":327,"type":4},"2007-06",{"date":329,"type":21},"2027-03",{"name":331,"class":45},"UConn Health",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":339,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":361},"100140521","assessing-changes-in-myocardial-tissue-and-blood-in-patients-with-advanced-heart-disease-100140521","NCT01099982","Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease","Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease, Effects of Mechanical Unloading on Myocardial Function and Structure in Humans","Inclusion Criteria:\n\n* \\>18 years of age diagnosed with heart failure undergoing either LVAD implantation or heart transplantation\n* 13 to 18 years of age, specifically, older children with heart failure whose body mass index is large enough to accommodate and LVAD\n\nExclusion Criteria:\n\n* Neither patient nor patient representative understands spoken English\n* Neither patient nor patient's personal representative is willing to give written consent for participation.","13 Years",{"count":341,"type":21},300,"Hypothesis:\n\nTissue and serum samples collected from end-stage heart failure patients receiving left ventricular assist device implantation (LVAD) or heart transplantation will provide information regarding the basic science of heart disease. Tissue and serum samples collected from a limited numbers of \"healthy controls\" (donor grafts that were not utilized for heart transplantation) will serve as a comparator in research database projects.\n\nDesign:\n\nThis is a registry project; there are no investigational treatments, drug or procedures associated with participation in registry activities. This project is an organized functional data and tissue data gathering and storing (database) endeavor with specific focus on the functional, structural, and molecular aspects of heart failure. Data collection will not immediately influence the course of treatment for any patient.",[27],[27,345,346,347,348,349,350,351],"Left Ventricular Assist Device","LVAD","Myocardium","Remodeling","Microvasculature","Fibrosis","Cardiac Transplant","2025-07-09",{"date":354,"type":38},"2025-07-15",{"date":356,"type":38},"2008-09",{"date":358,"type":21},"2028-01",{"name":360,"class":45},"University of Utah",3,{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":374,"conditions":375,"keywords":378,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":206},"100593586","phase-3-the-role-of-intraabdominal-pressure-and-point-of-care-ultrasound-to-guide-decongestive-therapy-in-heart-failure-100593586","NCT07008365","The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure","ABDOPOCUS-HF","Inclusion Criteria:\n\n* Men or women over 18 years of age.\n* Diagnosis of heart failure (HF) based on the latest HF guidelines published in 2022.\n* N-terminal pro b-type natriuretic peptide (NT-proBNP) \\> 1000 pg\u002FmL or Brain Natriuretic Peptide (BNP) \\> 250 pg\u002FmL.\n* Placement of a urinary catheter to allow for the measurement of intra-abdominal pressure.\n* Intravascular or mixed congestion pattern, defined as the presence of one or more clinical signs of congestion (edema, ascites, and\u002For pleural effusion).\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patient with a stay in the Internal Medicine department \\> 24 hours.\n* Absence of sufficient clinical congestion (ADVOR score = 0 at the time of randomization).\n* Patient\\'s refusal to participate in the clinical trial.\n* Inability or contraindication for urinary catheter placement.\n* Systolic blood pressure at admission \\< 100 mmHg.\n* Heart rate at admission \\> 170 beats per minute (bpm).\n* Cardiogenic shock.\n* Acute myocardial ischemia.\n* Patients receiving renal replacement therapy (ultrafiltration or peritoneal dialysis).\n* Kidney transplant recipients.\n* Serum hemoglobin \\< 9 g\u002FdL.\n* Pregnancy or breastfeeding.\n* History of hypersensitivity to hydrochlorothiazide or furosemide.\n* Patients admitted from the Intensive Care Unit.\n* Patients with recent cardiac surgery (within the last year) or heart transplant recipients.\n* Need for inotropic support to maintain adequate cardiac and\u002For renal output.","100 Years",{"count":371,"type":21},168,[373],"PHASE3","Systemic venous congestion is the primary therapeutic target of intravenous loop diuretics in patients admitted for acute heart failure (AHF). Despite their utility, a significant proportion of AHF patients are discharged with persistent clinical symptoms of congestion (residual congestion). Therefore, in recent years, there has been a growing focus on the use of tools (biomarkers, clinical ultrasound) that allow us to optimize diuretic treatment and thereby improve the prognosis of AHF patients. The objective is to analyze whether the strategy of guiding intravenous loop diuretic dosing based on intra-abdominal pressure(IAP) measurements and clinical ultrasound is superior to the conventional strategy employed in daily clinical practice. This study is a randomized, multicenter clinical trial involving consecutive patients admitted with a diagnosis of AHF in the Internal Medicine and Cardiology departments. Patients who meet the inclusion criteria, after signing informed consent, will be randomized into two groups: 1) Diuretic treatment guided by usual clinical practice and 2) Treatment guided by intra-abdominal pressure levels and clinical ultrasound (inferior vena cava and portal Doppler). This strategy will be maintained during the first 72 hours of admission, with a thorough analysis of congestion and diuretic response being conducted.",[140,27,376,377],"Intraabdominal Hypertension","Cardio-Renal Syndrome",[379,140,380,381,382],"Point of care Ultrasound (POCUS)","Cardio-renal syndrome","Intraabdominal pressure","Diuretic treatment","2025-06-04",{"date":385,"type":38},"2025-06-06",{"date":387,"type":38},"2025-03-10",{"date":389,"type":21},"2026-12-31",{"name":391,"class":45},"Instituto de Investigación Sanitaria Aragón",{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":361},"100362106","phase-1-peritoneal-ultrafiltration-in-cardio-renal-syndrome-100362106","NCT03994874","Peritoneal Ultrafiltration in Cardio Renal Syndrome.","Peritoneal Ultrafiltration in Cardio Renal Syndrome to Prevent Heart Failure Exacerbation.","PURE","Inclusion Criteria:\n\n* Age ≥18 yrs\n* Left ventricular ejection fraction ≤60%\n* NYHA Classification of III-IV despite guidelines directed medical therapy\n* Right ventricular failure due to after load mismatch, addressed by the presence of tricuspid calve regurgitation (≥ moderate) and by the disproportioned increase of the right atrial pressure (RAP) versus the capillary wedge pressure (CWP) with a ratio ≥0.65, detected with right heart catheterization performed after stable medical therapy according to international guidelines and comprehensive of loop diuretic (equivalent to furosemide oral dose till 2.0 mg\u002Fkg\u002Fday), coupled with urinary sodium excretion ≤ mEq\u002FL, confirmatory of loop diuretic resistance.\n* Cava vein enlargement (inner diameter, detected with focused echocardiography, between 1,5 and 2,5 cm, with respiratory collapse \\\u003C50% or absent due to intravascular fluid overload)\n* Decreased kidney function addressed by the measurement of glomerular filtration rate (GFR) urea clearance + creatinine clearance\u002F2 (\\>15 ml\u002Fmin\u002F1,73 m2)\n* NT pro-BNP plasma concentration \\> 1000 pg\u002Fml or BNP plasma concentration \\> 250 pg\u002Fml\n* at least one episode of pulmonary or systemic congestion requiring high-dose intravenous diuretics (or diuretic combinations) in the 6 months befor the study enrollment\n* An appropriate PUF technique candidate.\n* Signed informed consent\n\nExclusion Criteria:\n\n* Recipients of heart transplantation\n* Presence of a mechanical circulatory support device;\n* Hypertrophic obstructive cardiomyopathy;\n* Uncontrolled hypertension with systolic blood pressure ≥ 160 mmHg\n* Severe valvular stenosis;\n* Restrictive cardiomyopathy;\n* Acute coronary syndrome ≤ 6 months before;\n* Active myocarditis\n* Cardiosurgical or Endo-radiological heart procedures ≤ 6 months before\n* Cardiac resynchronization therapy (CRT) implantation or upgrading of pacemaker (PM) or implantable cardioverter defibrillator (ICD) to CRT ≤ 6 months before;\n* Patient with end-stage renal disease, GFR urea clearance + creatinine clearance\u002F2 (\\\u003C15 ml\u002Fmin\u002F1,73 m2 GFR)\n* Any major organ transplant (liver, lung, kidney)\n* Lung embolism ≤ 6 months before;\n* Fibrotic lung disease;\n* Liver Cirrhosis;\n* Absolute contraindication to peritoneal catheter implantation;\n* Logistical and or organizational contra-indication to treatment\n* Active malignancy;\n* Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical trial and for three months later\n* Female patients of childbearing age who do not use adequate contracteption.\n* Unwilling and unable to give informed consent;\n* Enrolment in another clinical trial involving medical or device based interventions.\n* Hypersensibility to IMP components.\n* Evidence of any condition that, according to the investigators' judgment, could expose the subject to undue risk and\u002For prevent the subject from participating in the study procedures and\u002For potentially afftecting the study quality data.",{"count":401,"type":21},84,[403,404],"PHASE1","PHASE2","Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).",[27],"2025-05-13",{"date":409,"type":38},"2025-05-16",{"date":411,"type":38},"2025-04-16",{"date":413,"type":21},"2027-06",{"name":415,"class":416},"Iperboreal Pharma Srl","INDUSTRY",{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":425,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":442},"100554192","phase-4-pvp-guided-decongestive-therapy-in-hf-2-100554192","NCT06495892","PVP-Guided Decongestive Therapy in HF 2","Peripheral Venous Pressure-Guided Decongestive Therapy in Heart Failure 2","PERIPHERAL-HF2","Inclusion criteria\n\n* Hospitalization for heart failure (de novo or decompensated chronic heart failure) irrespective of left ventricular ejection fraction\n* Age 18-99\n* Accept to participate\n\nExclusion criteria\n\n* A prior history of upper extremity venous disease\n* Serum creatinine ≥ 3.5 mg\u002FdL\n* Severe stenotic valvular disease\n* Hypertrophic obstructive cardiomyopathy\n* Withdrawal of consent\n* Indwelling central venous catheter,\n* Implanted left ventricular assist device\n* History of heart transplantation\n* Clinical diagnosis of cardiogenic shock\n* Any right-to-left shunt","99 Years",{"count":427,"type":21},650,[136],"The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.",[90,431,27],"Congestion","2024-12-01",{"date":434,"type":38},"2024-12-04",{"date":436,"type":38},"2024-07-01",{"date":438,"type":21},"2026-07-01",{"name":440,"class":441},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV",16,{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":17,"minAge":451,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":454,"briefSummary":455,"conditions":456,"keywords":459,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":46},"100513880","verifying-remote-monitoring-effect-on-net-cardiovascular-outcome-remoteverify-rve-100513880","NCT05971225","Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe)","Prospective Multicenter Observation Study on the Association Between Remote Monitoring and Clinical Outcome in Heart Failure Patients (Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe))","ReVe","Inclusion Criteria:\n\n* consented heart failure patients (LVEF\\\u003C=40%) with Biotronik wireless monitoring capable ICD\u002FCRTs aged \\>20 years\n* patients who are new to remote monitoring\n\nExclusion Criteria:\n\n* For patients with a life expectancy of less than 6 months. If patient do not understand the contents of wireless monitoring or it is difficult to fill out the consent form due to cognitive decline.\n\nIf wireless monitoring is performed with a patient enrolled in another clinical trial which remote monitoring may affect the previous enrolled study.","20 Years",{"count":453,"type":21},450,[24],"This study investigates the impact and safety of wireless monitoring on the prognosis of heart failure patients with implanted pacemakers and defibrillators. It aims to examine the frequency of unplanned early hospital visits and the early diagnosis\u002Fintervention of disease exacerbation based on the presence or absence of wireless monitoring. Additionally, the study analyzes the influence of wireless monitoring on the patient's disease progression as well as satisfaction of the study participants.",[27,457,458],"Defibrillators","Cardiac Resynchronization Therapy",[460,461,457,462],"remote monitoring","congestive heart failure","cardiac resynchronization therapy","2024-11-28",{"date":465,"type":38},"2024-12-03",{"date":467,"type":38},"2023-11-11",{"date":469,"type":21},"2027-04-30",{"name":471,"class":45},"Saint Vincent's Hospital, Korea",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":490,"locationsCount":153},"100508433","feasibility-and-success-trial-of-remote-patient-monitoring-in-heart-failure-100508433","NCT05900362","Feasibility and Success Trial of Remote Patient Monitoring in Heart Failure","FAST-RPM-HF","Inclusion Criteria:\n\n* A clinical diagnosis of heart failure\n* New York Heart Association Class II or III congestive HF symptoms\n* Admission to hospital within 12 months for symptomatic heart failure.\n* Own a smartphone or tablet or comfortable with using one\n* English as primary language\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Left Ventricular Ejection Fraction \\\u003C 35%\n* Implanted cardiac device (permanent pacemaker (PPM), implantable cardioverter defibrillator (ICD), chronic resynchronization therapy (CRT), implantable loop recorder (ILR))\n* CardioMEMS\n* Left ventricular assist device (LVAD)\n* NYHA Class I or IV congestive HF symptoms\n* Listed for cardiac transplant\n* Pregnant at time enrollment\n* End-stage renal disease","80 Years",{"count":81,"type":21},[24],"Previous research has investigated the use of remote patient monitoring in various clinical contexts, however there has not been a clinical trial examining use of the VitalCare platform for ambulatory management of heart failure. This trial will serve as a pilot study examining the feasibility of use of the VitalCare platform for ambulatory heart failure management and examine the effect of remote patient monitoring on patient engagement. To the investigators' knowledge, this will be the first study examining the effect of remote patient monitoring with the VitalCare platform on heart failure clinical outcomes, such as hospitalization for heart failure exacerbations and emergency room visits for heart failure.",[27],"2024-06-05",{"date":486,"type":38},"2024-06-06",{"date":488,"type":21},"2024-08-01",{"date":257,"type":21},{"name":491,"class":45},"Saint Luke's Health System",{"id":493,"slug":494,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":479,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":516},"100416528","phase-1-modulation-of-serca2a-of-intra-myocytic-calcium-trafficking-in-heart-failure-with-reduced-ejection-fraction-100416528","NCT04703842","Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction","A Phase 1\u002F2 Trial of the Safety and Efficacy of SRD-001 (AAV1\u002FSERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction","MUSIC-HFrEF1","Main Inclusion Criteria:\n\n* Chronic ischemic or non-ischemic cardiomyopathy\n* NYHA class III\u002FIV\n* LVEF ≤35%\n* Guideline-directed medical therapy for heart failure; ICD\n\nMain Exclusion Criteria:\n\n* Restrictive cardiomyopathy, hypertrophic cardiomyopathy, acute myocarditis, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease or discrete left ventricular (LV) aneurysm\n* Prior heart transplantation, left ventricular reduction surgery (LVRS), cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device), mechanical circulatory support device (MCSD) or cardiac shunt\n* Likely to receive cardiac resynchronization therapy, cardiomyoplasty, LVRS, conventional revascularization procedure or valvular repair in the 6 months following treatment\n* Likely need for an immediate heart transplant or MCSD implant due to hemodynamic instability\n* Inadequate hepatic and renal function\n* Diagnosis of, or treatment for, any cancer within the last 5 years except for basal cell carcinoma or carcinomas in situ where surgical excision was considered curative",{"count":501,"type":21},57,[403,404],"It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.",[27,505,90,506],"Heart Failure, Systolic","HFrEF - Heart Failure With Reduced Ejection Fraction","2024-03-24",{"date":509,"type":38},"2024-03-26",{"date":511,"type":38},"2021-09-23",{"date":513,"type":21},"2028-12",{"name":515,"class":416},"Sardocor Corp.",5,{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":4},"100478923","evaluating-clinical-trial-experiences-of-individuals-with-congestive-heart-failure-100478923","NCT05516290","Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure","An In Depth Study Investigating Patterns of Patients In Congestive Heart Failure Clinical Trials","Inclusion Criteria:\n\n* Lives in the United States\n* Is 18+ years old\n* Participant has a diagnosis of congestive heart failure\n* Participant has enrolled in an interventional clinical for congestive heart failure (self-reported)\n\nExclusion Criteria:\n\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form\n* No diagnosis of congestive heart failure confirmed",{"count":163,"type":21},"Clinical trial participation has always been substantially skewed toward certain demographic groups. However, there has been little study on whether trial qualities impact participation in either a positive or negative way. The goal of this research is to identify the characteristics that consistently restrict patients' ability to participate in or complete a trial in which they were initially interested. This data will be evaluated via a number of demographic lenses in order to find trends that could benefit future Congestive Heart Failure sufferers.",[27],[461,528],"heart failure","2023-12-29",{"date":531,"type":38},"2024-01-02",{"date":533,"type":21},"2024-09",{"date":40,"type":21},{"name":536,"class":416},"Power Life Sciences Inc."]